?

Log in

No account? Create an account

Previous Entry | Next Entry

http://www.independent.co.uk/life-style/health-and-families/health-news/cancer-shock-breakthrough-1710727.html

Ipilimumab is one of a class of drugs called monoclonal antibodies, which stimulate the body's own immune system to fight disease. The experimental treatment is being developed by Bristol-Myers Squibb and Medarex, a US biotech company. The drug is being trialled on malignant melanoma, the most serious form of skin cancer, Hodgkin's disease, lung cancer and prostate cancer. Studies are most advanced in melanoma, where it has been shown to prolong survival in patients with advanced forms of the disease. In the Mayo Clinic study of prostate cancer, researchers say that standard hormone treatment ignited the immune response, and adding ipilimumab was like "pouring gasoline on the pilot light".

Apparently it caused remarkable recession in several men's prostate cancers. During surgery the pathologists were having a hard time finding any remaining cancer cells.

Profile

moon
liveonearth
liveonearth

Latest Month

April 2019
S M T W T F S
 123456
78910111213
14151617181920
21222324252627
282930    

Tags

Powered by LiveJournal.com
Designed by chasethestars